title: Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
abstract: BACKGROUND
  The aim of this study is to examine the efficacy of long-term prophylaxis with lamivudine (LAM) after a course of post-operative hepatitis B immunoglobulin (HBIG) in patients who underwent liver transplantation (LT) for hepatitis B virus (HBV)-related disease.
  
  
  RESULTS
  The medical records of HBV-infected patients who underwent a LT in our institution between July 2001 and May 2005 were reviewed. There were 15 liver transplant recipients who were administered HBIG for <18 months and used LAM as a maintenance prophylaxis regime enrolled in this study. At enrollment, all patients were hepatitis B surface antigen (HBsAg) positive and three patients were HBeAg positive. There were 13 patients who were HBV DNA positive with a mean viral load of 5.4 log copies/mL, and among them, 12 recipients were on antiviral therapy with LAM (100 mg/d orally) for 12-168 d, resulting in HBV DNA negative levels in nine patients prior to their transplant. HBV recurrence post-LT was noted in two patients who had very high-HBV DNA levels pre-LT. Both of these patients showed LAM-resistant mutation at the time of recurrence. The 11 patients who were HBV DNA negative before LT (low-risk patients) had no HBV recurrence during a follow-up at a median of 58 months post-LT. This included five patients who had intermittent low-level HBV DNA post-LT (HBsAg negative), of whom two had YMDD mutation and these two were given adefovir in addition to LAM.
  
  
  CONCLUSIONS
  Our retrospective study demonstrated excellent long-term outcomes in the low-risk patients treated with LAM after a short course of HBIG.
authors.affiliation: Department of Hepatobiliary Surgery, Dalian Institute of Hepatobiliary Surgery, Dalian Friendship Hospital, Dalian, China.
authors.forename: M
authors.initials: M
authors.lastname: Yuefeng
authors.forename: F
authors.initials: F
authors.lastname: Weili
authors.forename: T
authors.initials: T
authors.lastname: Wenxiang
authors.forename: X
authors.initials: X
authors.lastname: Ligang
authors.forename: L
authors.initials: L
authors.lastname: Guiling
authors.forename: G
authors.initials: G
authors.lastname: Hongwei
authors.forename: L
authors.initials: L
authors.lastname: Wencai
authors.forename: W
authors.initials: W
authors.lastname: Xiaoguang
authors.forename: M
authors.initials: M
authors.lastname: Wei
authors.forename: F
authors.initials: F
authors.lastname: Zhongyi
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D004279:DNA, Viral; D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin